Rhenman & Partners Asset Management Ab Relay Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.02 Billion
- Q1 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 230,000 shares of RLAY stock, worth $2.05 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
230,000
Previous 390,000
41.03%
Holding current value
$2.05 Million
Previous $4.29 Million
55.53%
% of portfolio
0.19%
Previous 0.43%
Shares
4 transactions
Others Institutions Holding RLAY
# of Institutions
190Shares Held
127MCall Options Held
4.2KPut Options Held
1.7K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$249 Million2.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$106 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.8MShares$87.5 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY7.42MShares$66.3 Million4.98% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.88MShares$61.4 Million0.01% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $1.07B
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...